Weekly Endocrinology Research Analysis
This week highlighted mechanistic and translational advances that nominate tissue- and time-specific drivers of metabolic disease and actionable targets. A preclinical human-integrated study identifies adipocyte-specific sclerostin loop3–LRP4 signaling as a precision target to improve lipid and glucose metabolism. Endothelial FUNDC1 was shown to link vascular mitochondrial signaling to systemic insulin resistance via a SIRT3/GATA2/ET-1 axis. Human isotope-based diurnal phenotyping revealed night
Summary
This week highlighted mechanistic and translational advances that nominate tissue- and time-specific drivers of metabolic disease and actionable targets. A preclinical human-integrated study identifies adipocyte-specific sclerostin loop3–LRP4 signaling as a precision target to improve lipid and glucose metabolism. Endothelial FUNDC1 was shown to link vascular mitochondrial signaling to systemic insulin resistance via a SIRT3/GATA2/ET-1 axis. Human isotope-based diurnal phenotyping revealed nighttime insulin insufficiency as a key pathogenic window in MASLD, supporting chronotherapy approaches.
Selected Articles
1. Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism.
Combining human observations with in vitro and in vivo models, the study shows that sclerostin's loop3 interaction with adipocyte LRP4 mediates systemic dyslipidemia and dysglycemia; selective blockade of loop3–LRP4 in adipocytes reversed metabolic defects without engaging loop2 bone-targeted effects, suggesting a tissue-selective therapeutic strategy.
Impact: Identifies a precise adipose-specific mechanism by which a bone-derived factor perturbs systemic metabolism and proposes a safer, targeted alternative to existing anti-sclerostin agents that have cardiovascular warnings.
Clinical Implications: Supports development of loop3–LRP4–selective inhibitors to improve glucose and lipid control in patients (eg, postmenopausal osteoporosis with T2DM) while potentially mitigating cardiotoxic signals seen with loop2-targeting antibodies.
Key Findings
- Serum sclerostin is elevated in POP with T2DM and in newly diagnosed T2DM.
- Sclerostin loop3 contributes to whole-body lipid and glucose metabolic impairment in vivo.
- Adipocyte-specific blockade of loop3–LRP4 reverses sclerostin-induced metabolic defects in vitro and in vivo.
2. Endothelial FUNDC1 regulates metabolic reprogramming and the obesity-diabetes transition through the SIRT3/GATA2/endothelin-1 axis.
This multi-model study shows endothelial FUNDC1 upregulation in obesity/T2DM and that endothelial-specific Fundc1 deletion protects mice from HFD-induced obesity and insulin resistance by preventing SIRT3-L nuclear export, lowering GATA2 activity and ET-1 production, linking vascular mitochondrial signaling to systemic metabolic disease.
Impact: Defines a vascular mitochondria-to-nucleus signaling axis that causally links endothelial stress to systemic metabolic dysfunction and nominates FUNDC1/ET-1 as druggable nodes.
Clinical Implications: Points toward strategies to inhibit endothelial FUNDC1 signaling or modulate SIRT3-L/ET-1 pathways as potential means to prevent or mitigate insulin resistance and obesity-driven metabolic disease.
Key Findings
- Endothelial FUNDC1 expression is elevated in diabetic conditions and correlates with plasma ET-1 in obese/T2DM patients.
- Endothelial-specific Fundc1 deletion protects mice from HFD-induced obesity, insulin resistance and metabolic disorders.
- Overnutrition triggers FUNDC1-dependent nuclear export of SIRT3-L, disinhibiting GATA2 and enhancing ET-1 production.
3. Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night.
Using state-of-the-art stable isotope tracers and multi-tissue proteomics during day/night within-subject assessments, the study demonstrates that MASLD features pronounced nighttime hepatic and peripheral insulin resistance, increased DNL and NEFA exposure, and reduced plasma insulin availability due to lower secretion and greater clearance — a pathogenic nightly window that persists after weight-loss.
Impact: First human metabolic-flux study to map diurnal abnormalities in MASLD, defining night-time insulin insufficiency as a mechanistic target and providing a direct rationale for time-of-day interventions in lifestyle and pharmacotherapy.
Clinical Implications: Supports time-of-day–aware recommendations (earlier energy intake, evening insulin-sensitizing activity) and trials testing chronotherapy (timed dosing of agents affecting DNL or insulin dynamics) for MASLD management.
Key Findings
- Nighttime hepatic and peripheral insulin resistance, de novo lipogenesis, and systemic NEFA exposure are elevated in MASLD.
- Plasma insulin availability falls at night due to decreased secretion and increased clearance.
- Diurnal abnormalities persist after weight loss, and multi-tissue proteomics identify candidate time-varying molecular targets.